Our Services
Medical Information
Helpful Resources
Published on: 3/2/2026
Singulair side effects range from mild issues like headache or stomach pain to rare but serious mood and behavior changes that prompted an FDA Boxed Warning in 2020; children and those with mental health history may need closer monitoring.
Do not stop the medicine abruptly; medically approved next steps include talking to your doctor about risks, considering alternatives for mild allergies, closely monitoring mood, and seeking urgent help for suicidal thoughts or severe changes. There are several factors to consider, and important details on warning signs, who should be cautious, and how to safely switch or stop are outlined below.
If you or your child has asthma or allergies, your doctor may have prescribed Singulair (generic name: montelukast). Singulair has been widely used for years to help prevent asthma attacks and relieve symptoms of seasonal or year‑round allergies.
But you may have also heard concerns about Singulair side effects, especially those related to mood and behavior.
Let's walk through what Singulair does, what the research shows about side effects, and what medically approved next steps look like—so you can make informed, calm, and confident decisions.
Singulair (montelukast) is a prescription medication that works by blocking leukotrienes—chemicals in the body that cause inflammation, airway tightening, mucus production, and allergy symptoms.
Doctors prescribe Singulair for:
It is not a rescue inhaler and does not treat sudden asthma attacks.
Most people tolerate Singulair well. When side effects occur, they are often mild.
These typically resolve on their own and are not dangerous. However, persistent or worsening symptoms should be discussed with your doctor.
In 2020, the U.S. Food and Drug Administration (FDA) required a Boxed Warning (the strongest warning for prescription drugs) for Singulair due to reports of serious mental health side effects.
This does not mean these effects are common—but they are important enough to discuss clearly.
Some people developed symptoms during treatment. Others experienced symptoms after stopping Singulair.
The overall risk is considered low—but because these effects can be serious, awareness is critical.
The exact rate is difficult to determine. Clinical trials showed low rates of psychiatric events. However, post‑marketing reports (real-world use after approval) revealed enough concern for the FDA to act.
Important context:
The FDA now recommends that Singulair not be the first choice for mild allergy symptoms when safer alternatives are available.
Researchers are still studying this. Leukotrienes are involved in inflammation—but inflammation also interacts with the brain.
Blocking leukotrienes may affect:
Not everyone is affected, and we don't yet know why some people are more sensitive than others.
If you or your child takes Singulair, monitor for:
If you notice concerning changes in thinking, confusion, or other behavioral shifts, you can use a free AI-powered Alteration in mental status symptom checker to help you understand what you're experiencing and prepare for a conversation with your doctor.
This tool does not replace medical care—but it can help you organize symptoms before speaking to a healthcare professional.
If symptoms are severe, especially suicidal thoughts, seek immediate medical care.
Do not stop Singulair abruptly without speaking to your doctor unless symptoms are severe or life‑threatening.
For asthma patients, stopping medication without a plan can increase the risk of asthma attacks.
Instead:
In many cases, doctors will discontinue Singulair if concerning psychiatric symptoms develop.
Singulair may require extra caution in:
If Singulair is being considered for mild seasonal allergies, current medical guidance suggests weighing risks carefully since many alternative treatments exist.
If you are concerned about Singulair side effects, here's what doctors typically recommend:
Ask:
For mild allergic rhinitis, first-line treatments usually include:
For asthma control, alternatives may include:
Singulair may still be appropriate in some patients, especially when benefits clearly outweigh risks.
If continuing Singulair:
Early recognition prevents escalation.
If mental health symptoms appear:
It's important not to panic.
For many patients:
The goal is informed decision-making, not fear-based decision-making.
Every medication carries potential side effects. The key is weighing:
Call emergency services or go to the emergency room if there are:
These are medical emergencies.
Singulair remains an effective medication for many people with asthma and allergies. But awareness of potential side effects—especially mental health changes—is crucial.
If you notice mood or behavioral changes, do not ignore them. Using a free Alteration in mental status symptom checker can help you document what's happening and prepare questions for your doctor—but most importantly, speak to a healthcare professional as soon as possible.
Medication decisions should always be made in partnership with a qualified healthcare professional. If anything feels serious, life-threatening, or rapidly worsening, seek immediate medical care.
Staying informed—not alarmed—is the best way to protect your health.
(References)
* Srivastava, N., Srivastava, A., & Singh, P. (2021). Safety profile of montelukast: A systematic review. *Current drug safety, 16*(1), 58-69.
* Hadjialta, M. K., Tso, G. I., Varma, P., & Koulouris, A. E. (2022). Montelukast and neuropsychiatric events: A systematic review and meta-analysis. *Clinical Drug Investigation*, *42*(2), 127-137.
* Hadjialta, M. K., & Tso, G. I. (2023). Neuropsychiatric Adverse Events Associated With Montelukast in Children and Adolescents. *Current Allergy and Asthma Reports*, *23*(8), 353-358.
* Bayer, V., & Singh, T. (2022). The Montelukast Story: Pharmacovigilance, Regulatory Action, and the Risk-Benefit Balance. *Clinical Drug Investigation*, *42*(3), 209-216.
* Shukla, S., Pakhare, A. P., & Shrivastav, S. (2021). Recommendations for the safe and effective use of montelukast in pediatric asthma. *Pediatric pulmonology, 56*(6), 1856-1864.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.